HIMS stock is going bananas with the stock up nearly 200% YTD at one point. However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list. While ...

The stock is down 10.5% as 2 p.m. ET on Friday, while the stock is still up 224% in the last year. Here's why Hims & Hers stock fell this week. Where to invest $1,000 right now? Our analyst team ...

Hims & Hers reported its Q4 earnings this week. The company is growing quickly but faces a potential legal threat to its weight loss drug program. It is guiding for margin expansion and fast ...

While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no longer in short supply. The company makes compounded versions of ...

Hims & Hers has shown exceptional growth, with a 1,000% appreciation since our first bullish rating, driven by strong growth, margins, and strategic expansions. Despite the impressive ...

Hims & Hers Health Inc (NYSE:HIMS) stock has had a roller coaster week. The shares gapped higher by 17.5% on Tuesday despite a downgrade, unironically, to "equal-weight" from "overweight" at ...

Hims & Hers acquired a California-based peptide facility to strengthen its supply chain, improve quality control, and expand personalized tr The FDA announced the semaglutide shortage was resolved ...

The acquisition will strengthen the long-term durability of the company’s domestic supply chain, helping to ensure Americans can consistently access personalized medications. (Photo: Business ...

The acquisition closed in early February, and Hims & Hers expects to continue strengthening infrastructure capabilities as demand for personalized treatment continues to grow. For more information ...